Integer Holdings Co. (NYSE:ITGR) SVP Sells $565,700.00 in Stock

Integer Holdings Co. (NYSE:ITGR) SVP Andrew Senn sold 5,000 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $113.14, for a total value of $565,700.00. Following the completion of the sale, the senior vice president now owns 4,658 shares of the company’s stock, valued at $527,006.12. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Integer Trading Up 0.9 %

Integer stock opened at $114.16 on Friday. The stock has a 50-day moving average price of $114.74 and a 200 day moving average price of $102.06. The company has a market capitalization of $3.82 billion, a price-to-earnings ratio of 39.50, a price-to-earnings-growth ratio of 1.65 and a beta of 1.12. Integer Holdings Co. has a 52 week low of $69.40 and a 52 week high of $123.99. The company has a quick ratio of 2.01, a current ratio of 3.32 and a debt-to-equity ratio of 0.76.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a net margin of 6.01% and a return on equity of 11.25%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.87 earnings per share. Sell-side analysts anticipate that Integer Holdings Co. will post 5.27 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on ITGR shares. Benchmark reaffirmed a “buy” rating and issued a $130.00 price objective on shares of Integer in a research note on Friday, April 26th. KeyCorp boosted their price objective on shares of Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 9th. CL King initiated coverage on Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective on the stock. Finally, Bank of America upgraded shares of Integer from a “neutral” rating to a “buy” rating and raised their price target for the company from $105.00 to $135.00 in a report on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $120.50.

Institutional Trading of Integer

A number of hedge funds have recently modified their holdings of ITGR. GSA Capital Partners LLP acquired a new stake in Integer during the third quarter valued at $816,000. Dark Forest Capital Management LP boosted its position in Integer by 69.8% during the third quarter. Dark Forest Capital Management LP now owns 11,984 shares of the medical equipment provider’s stock worth $940,000 after purchasing an additional 4,926 shares in the last quarter. Legacy Wealth Asset Management LLC acquired a new stake in Integer in the fourth quarter valued at approximately $239,000. Trust Point Inc. purchased a new stake in shares of Integer in the fourth quarter valued at approximately $874,000. Finally, Nomura Holdings Inc. raised its stake in shares of Integer by 3.9% during the 3rd quarter. Nomura Holdings Inc. now owns 180,270 shares of the medical equipment provider’s stock worth $14,139,000 after buying an additional 6,731 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.